Clinical trial
Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
NCT00611858 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2008
- Completion date
- September 30, 2016
- Enrollment
- 13 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
rectal cancer